In a peer exchange moderated by Dr. Peter Salgo, Hugh Fatodu and Drs. Patrick F. Fogarty, Maria Lopes, and Michelle Petri share their insights on the evolving dynamics of rare diseases in contemporary healthcare and managed care, and specifically address the implications for hemophilia and systemic lupus erythematosus (SLE). In the US, a rare disease is defined as a condition that affects than 200,000 persons. However, despite the 25 million American lives currently affected by more than 7,000 identified rare diseases, the patient and provider communities are still plagued by a general lack of awareness, a high risk for misdiagnosis, and a scarcity of treatment options. There is an acknowledgement among the panelists that the early recognition of diseases such as hemophilia and SLE has “very significant” implications for therapy, perhaps life-changing and even life-saving.
Trump Administration’s Message to Supreme Court Puts New Wrinkle in Braidwood Case
February 21st 2025The Trump administration argues that HHS Secretary Robert F. Kennedy Jr can overrule the US Preventive Services Task Force to determine the preventive services covered under the Affordable Care Act.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
5 Key Health Care Moments During President Trump's First Month Back in Office
February 21st 2025President Donald J. Trump pushed for significant health care changes during his first month back in office, through executive orders affecting managed care, drug pricing, and clinical trial diversity guidance.
Read More
NSCLC Advancements Offer Hope, but Disparities Persist
February 20th 2025Ioana Bonta, MD, Georgia Cancer Specialists, discusses the evolving state of non-small cell lung cancer (NSCLC) treatments, their impact on patient outcomes, and the need to address ongoing disparities in these populations.
Read More